» Articles » PMID: 30469417

ZIKV Demonstrates Minimal Pathologic Effects and Mosquito Infectivity in Viremic Cynomolgus Macaques

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2018 Nov 25
PMID 30469417
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the effects of ZIKV infection on non-human primates (NHPs), as well as to investigate whether these NHPs develop sufficient viremia to infect the major urban vector mosquito, , four cynomolgus macaques () were subcutaneously infected with 5.0 log focus-forming units (FFU) of DNA clone-derived ZIKV strain FSS13025 (Asian lineage, Cambodia, 2010). Following infection, the animals were sampled (blood, urine, tears, and saliva), underwent daily health monitoring, and were exposed to at specified time points. All four animals developed viremia, which peaked 3⁻4 days post-infection at a maximum value of 6.9 log genome copies/mL. No virus was detected in urine, tears, or saliva. Infection by ZIKV caused minimal overt disease: serum biochemistry and CBC values largely fell within the normal ranges, and cytokine elevations were minimal. Strikingly, the minimally colonized population of exposed to viremic animals demonstrated a maximum infection rate of 26% during peak viremia, with two of the four macaques failing to infect a single mosquito at any time point. These data indicate that cynomolgus macaques may be an effective model for ZIKV infection of humans and highlights the relative refractoriness of for ZIKV infection at the levels of viremia observed.

Citing Articles

Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.

Wang S, Li W, Wang Z, Yang W, Li E, Xia X Signal Transduct Target Ther. 2024; 9(1):223.

PMID: 39256346 PMC: 11412324. DOI: 10.1038/s41392-024-01917-x.


Predicting Efficacy of a Purified Inactivated Zika Virus Vaccine in Flavivirus-Naïve Humans Using an Immunological Correlate of Protection in Non-Human Primates.

Acosta C, Nordio F, Boltz D, Baldwin W, Hather G, Kpamegan E Microorganisms. 2024; 12(6).

PMID: 38930559 PMC: 11206130. DOI: 10.3390/microorganisms12061177.


Trade-offs shaping transmission of sylvatic dengue and Zika viruses in monkey hosts.

Hanley K, Cecilia H, Azar S, Moehn B, Gass J, Oliveira da Silva N Nat Commun. 2024; 15(1):2682.

PMID: 38538621 PMC: 10973334. DOI: 10.1038/s41467-024-46810-x.


Shows Increased Susceptibility to Zika Virus via Both In Vitro and In Vivo Models of Type II Diabetes.

Azar S, Campos R, Yun R, Strange T, Rossi S, Hanley K Viruses. 2022; 14(4).

PMID: 35458395 PMC: 9024453. DOI: 10.3390/v14040665.


Low Vector Competence for Zika Virus from Viremic Rhesus Macaques.

Fernandes R, David M, Abreu F, Ferreira-de-Brito A, Gardinali N, Lima S Viruses. 2020; 12(12).

PMID: 33255150 PMC: 7759330. DOI: 10.3390/v12121345.


References
1.
Brasil P, Carvalho Sequeira P, dAvila Freitas A, Zogbi H, Amaral Calvet G, de Souza R . Guillain-Barré syndrome associated with Zika virus infection. Lancet. 2016; 387(10026):1482. DOI: 10.1016/S0140-6736(16)30058-7. View

2.
Larocca R, Abbink P, Peron J, Zanotto P, Iampietro M, Badamchi-Zadeh A . Vaccine protection against Zika virus from Brazil. Nature. 2016; 536(7617):474-8. PMC: 5003703. DOI: 10.1038/nature18952. View

3.
Gubler D, Suharyono W, Lubis I, Eram S, Gunarso S . Epidemic dengue 3 in central Java, associated with low viremia in man. Am J Trop Med Hyg. 1981; 30(5):1094-9. DOI: 10.4269/ajtmh.1981.30.1094. View

4.
Nalca A, Fellows P, Whitehouse C . Vaccines and animal models for arboviral encephalitides. Antiviral Res. 2003; 60(3):153-74. DOI: 10.1016/j.antiviral.2003.08.001. View

5.
Musso D, Rouault E, Teissier A, Lanteri M, Zisou K, Broult J . Molecular detection of Zika virus in blood and RNA load determination during the French Polynesian outbreak. J Med Virol. 2016; 89(9):1505-1510. PMC: 5575554. DOI: 10.1002/jmv.24735. View